DYN - NASDAQ

Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc.

DYNยทNASDAQ

$17.99

-3.4%
HealthcareBiotechnology

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$2.97B
EPS-3.4700
P/E Ratio-5.18
Earnings Date07/27/2026
Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc. Fair Value Envelope

DYN ยท NASDAQ

Our analysis suggests that DYN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $17.99, this represents a potential HIDDEN relative to our calculated worth for Dyne Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $17.99

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$553.1M
+ Cash & Equivalents$893.4M
Firm Value$340.3M
- Debt$20.3M
Equity Value$320.0M
/ Shares Outstanding142,824,687B
DCF Value$2
OVERVALUED BY 88%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$252.2M
-$157.8M
-$98.7M
-$61.7M
-$38.6M
-$24.1M
-$15.1M
-$9.4M
-$5.9M
-$3.7M
Maintenance CapEx
-$240.2K
-$150.2K
-$94.0K
-$58.8K
-$36.8K
-$23.0K
-$14.4K
-$9.0K
-$5.6K
-$3.5K
Owner Earnings
-$252.4M
-$157.9M
-$98.8M
-$61.8M
-$38.6M
-$24.2M
-$15.1M
-$9.5M
-$5.9M
-$3.7M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$233.7M
-$135.4M
-$78.4M
-$45.4M
-$26.3M
-$15.2M
-$8.8M
-$5.1M
-$3.0M
-$1.7M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your DYN research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.